|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||82.09 - 82.48|
|52 Week Range||52.29 - 84.21|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||53.75|
|Forward Dividend & Yield||1.29 (1.56%)|
|Ex-Dividend Date||Mar 27, 2020|
|1y Target Est||N/A|
Moody's Investors Service, ("Moody's") today affirmed the Baa1 issuer rating of Givaudan SA (Givaudan) and revised the outlook to negative from stable. The outlook revision to negative from stable reflects Moody's expectation that the string of bolt-on acquisitions announced by Givaudan since taking over Naturex in September 2018 will leave its leverage metrics weakly positioned in the next 12-18 months and delay the deleveraging required to underpin its rating at the Baa1 level.
Moody's Investors Service, ("Moody's") has assigned a B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating (PDR) to Innophos Holdings, Inc. ("Innophos"). Moody's has also assigned a B1 rating to the proposed $415 million senior secured first lien term loan and a Caa1 rating to the proposed $300 million senior unsecured notes.
Moody's Investors Service, ("Moody's") affirmed the Baa3 ratings of International Flavors and Fragrances, Inc. ("IFF") and its Prime-3 rating for commercial paper. The outlook revision follows the announcement that IFF has signed a definitive agreement to merge with the DuPont De Nemours, Inc.'s ("DuPont") Nutrition and Biosciences business for approximately $26.2 billion in cash and equity. "The negative outlook reflects the significant size of the transaction, the remaining integration risk from the Frutarom transaction and the lack of a consistent growth record at DuPont's Nutrition and Biosciences ("N&B") business, as well as credit metrics that are not reflective of the Baa3 rating" said Domenick R. Fumai, Moody's Vice President and lead analyst for IFF.